CD8A and neoplasm: Anti-PD-1/PD-L1 mAb can increase the expression level of A2aR [73], and the activation of A2aR enhances the expression of PD-1 on tumor-specific CD8+ T cells and CD4+ Foxp3+ Treg cells.